POSEIDA THERAP. DL-0001
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies an… Read more
Market Cap & Net Worth: POSEIDA THERAP. DL-0001 (2RZ)
POSEIDA THERAP. DL-0001 (F:2RZ) has a market capitalization of $905.42 Million (€882.07 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #9396 globally and #1009 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying POSEIDA THERAP. DL-0001's stock price €9.05 by its total outstanding shares 97466704 (97.47 Million).
POSEIDA THERAP. DL-0001 Market Cap History: 2020 to 2025
POSEIDA THERAP. DL-0001's market capitalization history from 2020 to 2025. Data shows change from $920.43 Million to $905.42 Million (-5.36% CAGR).
POSEIDA THERAP. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how POSEIDA THERAP. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2RZ by Market Capitalization
Companies near POSEIDA THERAP. DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to POSEIDA THERAP. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
POSEIDA THERAP. DL-0001 Historical Marketcap From 2020 to 2025
Between 2020 and today, POSEIDA THERAP. DL-0001's market cap moved from $920.43 Million to $ 905.42 Million, with a yearly change of -5.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €905.42 Million | +2.84% |
| 2024 | €880.41 Million | +183.87% |
| 2023 | €310.15 Million | -35.68% |
| 2022 | €482.23 Million | -20.33% |
| 2021 | €605.28 Million | -34.24% |
| 2020 | €920.43 Million | -- |
End of Day Market Cap According to Different Sources
On Jan 6th, 2026 the market cap of POSEIDA THERAP. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $905.42 Million USD |
| MoneyControl | $905.42 Million USD |
| MarketWatch | $905.42 Million USD |
| marketcap.company | $905.42 Million USD |
| Reuters | $905.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.